Literature DB >> 28084594

Caspase-Cleaved Tau Impairs Mitochondrial Dynamics in Alzheimer's Disease.

María José Pérez1, Katiana Vergara-Pulgar1, Claudia Jara1, Fabian Cabezas-Opazo1, Rodrigo A Quintanilla2,3.   

Abstract

Alzheimer's disease (AD) is characterized by the presence of aggregates of tau protein. Tau truncated by caspase-3 (D421) or tau hyperphosphorylated at Ser396/S404 might play a role in the pathogenesis of AD. Mitochondria are dynamic organelles that modify their size and function through mitochondrial dynamics. Recent studies have shown that alterations of mitochondrial dynamics affect synaptic communication. Therefore, we studied the effects of pathological forms of tau on the regulation of mitochondrial dynamics. We used primary cortical neurons from tau(-/-) knockout mice and immortalized cortical neurons (CN1.4) that were transfected with plasmids containing green fluorescent protein (GFP) or GFP with different tau forms: full-length (GFP-T4), truncated (GFP-T4C3), pseudophosphorylated (GFP-T42EC), or both truncated and pseudophosphorylated modifications of tau (GFP-T4C3-2EC). Cells expressing truncated tau showed fragmented mitochondria compared to cells that expressed full-length tau. These findings were corroborated using primary neurons from tau(-/-) knockout mice that expressed the truncated and both truncated and pseudophosphorylated forms of tau. Interestingly, mitochondrial fragmentation was accompanied by a significant reduction in levels of optic atrophy protein 1 (Opa1) in cells expressing the truncated form of tau. In addition, treatment with low concentrations of amyloid-beta (Aβ) significantly reduced mitochondrial membrane potential, cell viability, and mitochondrial length in cortical cells and primary neurons from tau(-/-) mice that express truncated tau. These results indicate that the presence of tau pathology impairs mitochondrial dynamics by reducing Opa1 levels, an event that could lead to mitochondrial impairment observed in AD.

Entities:  

Keywords:  Alzheimer’s disease; Mitochondria; Neurodegeneration; Opa1; Tau

Mesh:

Substances:

Year:  2017        PMID: 28084594     DOI: 10.1007/s12035-017-0385-x

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  56 in total

Review 1.  Alzheimer's disease.

Authors:  Henry W Querfurth; Frank M LaFerla
Journal:  N Engl J Med       Date:  2010-01-28       Impact factor: 91.245

Review 2.  Dynamin-related protein 1 and mitochondrial fragmentation in neurodegenerative diseases.

Authors:  P Hemachandra Reddy; Tejaswini P Reddy; Maria Manczak; Marcus J Calkins; Ulziibat Shirendeb; Peizhong Mao
Journal:  Brain Res Rev       Date:  2010-12-08

3.  Tau facilitates Aβ-induced loss of mitochondrial membrane potential independent of cytosolic calcium fluxes in mouse cortical neurons.

Authors:  Susanne P Pallo; Gail V W Johnson
Journal:  Neurosci Lett       Date:  2015-04-15       Impact factor: 3.046

4.  Caspase-cleaved tau expression induces mitochondrial dysfunction in immortalized cortical neurons: implications for the pathogenesis of Alzheimer disease.

Authors:  Rodrigo A Quintanilla; Tori A Matthews-Roberson; Philip J Dolan; Gail V W Johnson
Journal:  J Biol Chem       Date:  2009-04-23       Impact factor: 5.157

5.  Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology.

Authors:  Robert A Rissman; Wayne W Poon; Mathew Blurton-Jones; Salvatore Oddo; Reidun Torp; Michael P Vitek; Frank M LaFerla; Troy T Rohn; Carl W Cotman
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

6.  Amyloid-beta and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer's disease mice.

Authors:  Virginie Rhein; Xiaomin Song; Andreas Wiesner; Lars M Ittner; Ginette Baysang; Fides Meier; Laurence Ozmen; Horst Bluethmann; Stefan Dröse; Ulrich Brandt; Egemen Savaskan; Christian Czech; Jürgen Götz; Anne Eckert
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-06       Impact factor: 11.205

Review 7.  Multiple faces of dynamin-related protein 1 and its role in Alzheimer's disease pathogenesis.

Authors:  Ramesh Kandimalla; P Hemachandra Reddy
Journal:  Biochim Biophys Acta       Date:  2015-12-17

8.  Loss of OPA1 disturbs cellular calcium homeostasis and sensitizes for excitotoxicity.

Authors:  Y E Kushnareva; A A Gerencser; B Bossy; W-K Ju; A D White; J Waggoner; M H Ellisman; G Perkins; E Bossy-Wetzel
Journal:  Cell Death Differ       Date:  2012-11-09       Impact factor: 15.828

9.  Mitochondrial division ensures the survival of postmitotic neurons by suppressing oxidative damage.

Authors:  Yusuke Kageyama; Zhongyan Zhang; Ricardo Roda; Masahiro Fukaya; Junko Wakabayashi; Nobunao Wakabayashi; Thomas W Kensler; P Hemachandra Reddy; Miho Iijima; Hiromi Sesaki
Journal:  J Cell Biol       Date:  2012-05-07       Impact factor: 10.539

Review 10.  Mitochondrial Dysfunction Contributes to the Pathogenesis of Alzheimer's Disease.

Authors:  Fabian A Cabezas-Opazo; Katiana Vergara-Pulgar; María José Pérez; Claudia Jara; Cesar Osorio-Fuentealba; Rodrigo A Quintanilla
Journal:  Oxid Med Cell Longev       Date:  2015-06-29       Impact factor: 6.543

View more
  19 in total

Review 1.  Roles of tau protein in health and disease.

Authors:  Tong Guo; Wendy Noble; Diane P Hanger
Journal:  Acta Neuropathol       Date:  2017-04-06       Impact factor: 17.088

2.  Tau phosphorylation and OPA1 proteolysis are unrelated events: Implications for Alzheimer's Disease.

Authors:  Marcel V Alavi
Journal:  Biochim Biophys Acta Mol Cell Res       Date:  2021-08-13       Impact factor: 4.739

Review 3.  The use of fibroblasts as a valuable strategy for studying mitochondrial impairment in neurological disorders.

Authors:  Margrethe A Olesen; Francisca Villavicencio-Tejo; Rodrigo A Quintanilla
Journal:  Transl Neurodegener       Date:  2022-07-04       Impact factor: 9.883

Review 4.  Amyloid-β and tau complexity - towards improved biomarkers and targeted therapies.

Authors:  Juan Carlos Polanco; Chuanzhou Li; Liviu-Gabriel Bodea; Ramon Martinez-Marmol; Frederic A Meunier; Jürgen Götz
Journal:  Nat Rev Neurol       Date:  2017-12-15       Impact factor: 42.937

Review 5.  Synergy between amyloid-β and tau in Alzheimer's disease.

Authors:  Marc Aurel Busche; Bradley T Hyman
Journal:  Nat Neurosci       Date:  2020-08-10       Impact factor: 24.884

6.  Activation of the Melanocortin-4 Receptor Prevents Oxidative Damage and Mitochondrial Dysfunction in Cultured Hippocampal Neurons Exposed to Ethanol.

Authors:  Rodrigo A Quintanilla; María José Pérez; Alejandra Aranguiz; Carola Tapia-Monsalves; Gloria Mendez
Journal:  Neurotox Res       Date:  2020-05-06       Impact factor: 3.911

7.  Structure-Based Design and Biological Evaluation of Novel Caspase-2 Inhibitors Based on the Peptide AcVDVAD-CHO and the Caspase-2-Mediated Tau Cleavage Sequence YKPVD314.

Authors:  Merlin Bresinsky; Jessica M Strasser; Bernadette Vallaster; Peng Liu; William M McCue; Jessica Fuller; Alexander Hubmann; Gurpreet Singh; Kathryn M Nelson; Matthew E Cuellar; Carrie M Wilmot; Barry C Finzel; Karen H Ashe; Michael A Walters; Steffen Pockes
Journal:  ACS Pharmacol Transl Sci       Date:  2022-01-05

Review 8.  The Association of Tau With Mitochondrial Dysfunction in Alzheimer's Disease.

Authors:  Ying Cheng; Feng Bai
Journal:  Front Neurosci       Date:  2018-03-22       Impact factor: 4.677

Review 9.  Reciprocal Interactions of Mitochondria and the Neuroimmunoendocrine System in Neurodegenerative Disorders: An Important Role for Melatonin Regulation.

Authors:  Victoria O Polyakova; Igor M Kvetnoy; George Anderson; Jessica Rosati; Gianluigi Mazzoccoli; Natalya S Linkova
Journal:  Front Physiol       Date:  2018-03-12       Impact factor: 4.566

Review 10.  Contribution of Tau Pathology to Mitochondrial Impairment in Neurodegeneration.

Authors:  María J Pérez; Claudia Jara; Rodrigo A Quintanilla
Journal:  Front Neurosci       Date:  2018-07-05       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.